drugset / Trial / NCT01686711

A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322

NCT01686711

Phase 4 Completed 207 enrolled Takeda
Parallel-groupTreatment

Summary

To evaluate the efficacy and safety of coadministration AD-4833 and SYR-322 in patients with diabetes mellitus.

Timeline

Start
2012-09
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 15 mg Oral
Subject Pioglitazone Small molecule 30 mg Oral